The Tradr 2X Long SRPT Daily ETF (SRPU) seeks to provide 200% of the daily performance of Sarepta Therapeutics Inc. (SRPT), a biotechnology company focused on developing RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy treatments.
How It Works
SRPU uses derivatives including swaps and futures contracts to achieve twice the daily return of SRPT stock through active management. The fund resets its leverage daily, meaning it targets 2x exposure based on each day's closing price rather than maintaining consistent leverage over longer periods. Holdings consist primarily of financial instruments rather than direct stock ownership, with positions adjusted daily to maintain the 2x target exposure.
Key Features
- Provides 2x leveraged exposure to single biotech stock SRPT, amplifying both gains and losses from the underlying company's performance
- Daily rebalancing ensures precise 2x exposure each trading day but creates compounding effects over multi-day holding periods
- Recently launched in October 2025, offering focused exposure to RNA therapeutics and rare disease treatment development sector
Risks
- This ETF can lose value rapidly if SRPT stock declines, with losses amplified to twice the underlying stock's daily decline
- Daily reset mechanism causes compounding effects that deviate from 2x returns over periods longer than one day, potentially resulting in significant tracking error
- Single-stock concentration risk means biotechnology regulatory failures, clinical trial setbacks, or competitive threats to SRPT directly impact the entire fund
Who Should Own This
Suitable only for sophisticated traders with very high risk tolerance and intraday to few-day time horizons. Requires active monitoring and should represent less than 5% of total portfolio. Best used for short-term tactical bets on SRPT earnings, clinical trial results, or biotech sector momentum rather than long-term investing.